Henry Schein (NASDAQ:HSIC) Given New $80.00 Price Target at UBS Group

Henry Schein (NASDAQ:HSIC) had its price objective decreased by UBS Group from $82.00 to $80.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s price target points to a potential upside of 11.42% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group increased their price target on Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, March 6th. Leerink Partnrs restated a “market perform” rating on shares of Henry Schein in a research note on Monday, February 26th. Evercore ISI increased their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research note on Wednesday, February 28th. Piper Sandler boosted their target price on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $81.55.

Henry Schein Stock Up 0.8 %

Shares of NASDAQ:HSIC traded up $0.60 during trading on Wednesday, reaching $71.80. 109,970 shares of the stock traded hands, compared to its average volume of 1,088,078. The stock has a market cap of $9.22 billion, a P/E ratio of 22.79, a price-to-earnings-growth ratio of 1.68 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. The stock has a 50-day moving average of $73.08 and a two-hundred day moving average of $72.34. Henry Schein has a 52-week low of $60.01 and a 52-week high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.21 billion. During the same quarter in the previous year, the business earned $1.21 earnings per share. The company’s revenue was up 3.7% on a year-over-year basis. As a group, sell-side analysts expect that Henry Schein will post 5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

Several large investors have recently added to or reduced their stakes in HSIC. Raymond James Financial Services Advisors Inc. increased its holdings in Henry Schein by 15.8% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 7,057 shares of the company’s stock worth $524,000 after buying an additional 965 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Henry Schein by 8.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,528 shares of the company’s stock worth $1,747,000 after purchasing an additional 1,773 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Henry Schein by 0.9% in the third quarter. Mackenzie Financial Corp now owns 62,672 shares of the company’s stock valued at $4,577,000 after purchasing an additional 562 shares during the last quarter. Strs Ohio grew its position in Henry Schein by 13.6% during the 3rd quarter. Strs Ohio now owns 30,886 shares of the company’s stock worth $2,293,000 after purchasing an additional 3,687 shares during the period. Finally, IFM Investors Pty Ltd raised its stake in shares of Henry Schein by 11.8% during the 3rd quarter. IFM Investors Pty Ltd now owns 27,540 shares of the company’s stock valued at $2,045,000 after buying an additional 2,914 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.